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Abstract The aim of the present study was to determine
the profile of different inflammatory molecules in serum
and cerebrospinal fluid (CSF) during invasive meningococ-
cal disease (IMD). Their relationship with IMD severity
was also assessed. A cohort of 12 patients with IMD was
investigated. Paired serum and CSF samples were obtained
at the time of diagnostic and follow-up lumbar puncture
and were examined using Luminex® analysis. IMD severity
correlated with serum interleukin-6 (IL-6) and interleukin-1
receptor antagonist (IL-1ra) on admission. Furthermore, the
CSF levels of IL-1β, IL-1ra, IL-6, IL-8, macrophage
inflammatory protein-1β (MIP-1β), and monocyte chemo-
attractant protein-1 (MCP-1) were significantly higher than
their respective serum levels. The strongest correlations
were found between serum concentrations of IL-1β and IL-
1ra, IL-6, IL-8, and MIP-1β, whereas the strongest
correlations in CSF were found between endotoxin and
IL-8, IL-17, MIP-1β, and MCP-1. As was expected, the
concentrations of inflammatory molecules in both serum
and CSF significantly decreased after antibiotic treatment.
With regard to kinetics, a severe course of IMD correlated
positively with rapid declines of CSF IL-6 and cortisol
levels. Sequential multiple analyses revealed patterns of
inflammatory responses that were associated with the
severity of IMD, as well as with the compartmentalization
and kinetics of the immune reaction.
Introduction
Invasive meningococcal disease (IMD) still remains a life-
threatening infection with significant morbidity and mor-
tality. This remains true even in developed countries, in
spite of the availability of efficient antimicrobial therapy
and intensive care treatment. IMD can present in four
different clinical forms: benign meningococcemia (mortal-
ity rate <1%), meningitis (mortality rate ∼5%), meningitis
with sepsis (mortality rate ∼10%), and fulminant meningo-
coccal sepsis (FMS; mortality rate 40–50%). Important
mechanisms involved in IMD pathogenesis include the
massive production of inflammatory mediators (i.e., com-
plement factors, cytokines, etc.) and excessive activation of
the coagulation and fibrinolysis pathways [1, 2]. Exagger-
ated production of these mediators during the initial course
of IMD is associated with high levels of meningococcal
lipooligosaccharides (LOS) released into body fluids by
Neisseria meningitidis, the causative agent of IMD [3].
High LOS concentrations are believed to be responsible for
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e-mail: michal.holub@lf1.cuni.czthe over-stimulation of innate immunity through toll-like
receptors (TLRs) and coagulation systems, leading to
potentially fatal complications of IMD, which include
multiple organ failure, septic shock, and disseminated
intravascular coagulation with bleeding complications [4].
The principles of IMD management have been almost
the same over the last few decades: rapid clinical
diagnostics, immediate administration of efficient anti-
biotics, and transfer to a specialized intensive care unit
(ICU). Novel therapies that can be used in the ICU setting
include the administration of recombinant human activated
protein C (rhAPC), which is indicated especially in adult
patients with FMS without bleeding complications [5]. A
significant effort has also been devoted to the neutralization
of LOS. Unfortunately, the studies that have been con-
ducted were not powerful enough to demonstrate improved
survival [6, 7]. Thus, no new therapies for IMD have been
approved since the advent of rhAPC in 2001. Moreover, a
clinical trial in children with IMD treated with rhAPC,
which has both anti-inflammatory and anticoagulant prop-
erties, was inconclusive [8]. This lack of progress in the
development of new therapies is partly due to our
insufficient knowledge about the complexities of innate
immunity responses during the course of IMD.
Therefore, the aim of our study was to better characterize
the profiles of cytokines and other inflammatory mediators
in the serum and cerebrospinal fluid (CSF) during IMD
using a multiplex assay. We also assessed the relationship
between the investigated mediators in both compartments
and their correlation with IMD severity. Additionally,
changes in these profiles after starting IMD therapy were
evaluated.
Patients and methods
This study was conducted at the Teaching Hospital
Bulovka, a 1,209-bed, tertiary care community hospital in
Prague, Czech Republic. Enrolled patients were admitted to
the Department of Infectious Diseases between the years
2004 and 2006. The study was approved by the local ethics
committee, and it was performed in compliance with the
Helsinki Declaration (1996 revision).
Patients
A cohort of 12 patients (five females and seven males) with
IMD was analyzed. The mean age of the study subjects was
21 years (range 14–52 years). Table 1 presents the patient
demographics and clinical parameters, as well as the
characteristics of N. meningitidis strains determined by
classical and molecular methods (i.e., polymerase chain
reaction [PCR], genosubtyping, porA sequencing, and
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Patients’ specimens (i.e., paired serum and CSF samples)
were obtained at the time of diagnostic (day 1) and follow-
up (day 3–5) lumbar puncture. Table 2 shows the patients’
laboratory results from routine blood and CSF tests at day
1. CSF samples were collected in polystyrene tubes closed
with screw-caps (Sarstedt AG, Germany) and venous blood
was collected using an S-Monovette® (Sarstedt AG)
collection system for blood count determination in tubes
with K3-EDTA (Sarstedt AG). All samples were centri-
fuged immediately after collection, aliquoted, and stored at
−80°C until further analyses were performed. The patients
were treated according to the national standard protocol,
which consists of antibiotics (third-generation cephalospor-
ins for meningitis and for sepsis + meningitidis or penicillin
G for FMS), corticosteroids (for meningitis), and intensive
care treatment, if required [13]. The disease severity was
evaluated using the APACHE II (Acute Physiological and
Chronic Health Evaluation), SOFA (Sequential Organ
Failure Assessment), and GCS (Glasgow Coma Scale)
scoring systems.
Laboratory methods
In addition to routine analyses (i.e., differential blood
count, CSF cytology and chemistry, and serum level of C-
reactive protein [S-CRP]), serum and CSF concentrations
of 14 biomarkers (i.e., interleukin-1β [IL-1β], IL-1 receptor
antagonist [IL-1ra], IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-
12, IL-17, tumor necrosis factor α [TNF-α], monocyte
chemoattractant protein 1 [MCP-1], macrophage inflamma-
tory protein 1β [MIP-1β], and leptin) were analyzed using
the Luminex® methodology with reagents from R&D
Systems, Inc. (USA). Endotoxin concentrations were
measured using the Kinetic LAL assay (Cambrex, USA).
Analyses of cortisol levels in the CSF and serum were
performed by radioimmunometric assay using a commer-
cial DSL-2000 kit (Diagnostic Systems Laboratories, USA)
with a detection limit of 5 nmol/l.
Statistical methods
Statistical analyses were performed using SPSS software™
(Jandel Scientific, USA). The data are presented as means
(standard deviation). The analyses consisted of two-tailed tests
with an α-level below 0.05. The differences between serum
and CSF levels were tested using paired t-tests and Wilcox-
on’s signed rank test for nonparametric data. Spearman’sa n d
Pearson’s correlation tests were employed to determine
whether correlations existed between clinical and laboratory
parameters.
Results
Cytokines, chemokines, leptin, and endotoxin in serum
and CSF at admission
IL-1β w a sd e t e c t e di nt h es e r u mi n4 1 %o fp a t i e n t s( 5 / 1 2 ) ,
whereas it was detected in the CSF in 100% of patients (10/10).
IL-1ra was detected in 100% of serum specimens (12/12), as
well as in 100% of CSF samples (10/10). IL-6 was detected in
91% of serum samples (11/12), whereas CSF concentrations
were detectable in 100% of specimens (10/10). IL-10 was
detectable in 75% of patients (9/12) in the serum and in 90%
of patients in the CSF (9/10). IL-17 was detected in 41% of
serum specimens (5/12) and in 50% of CSF samples (5/10).
TNF-α levels were detectable in the serum of only 25% of
patients (3/12) and in the CSF in only 10% of the specimens
(1/10). IL-8 was detectable in 91% of serum specimens
Patient
no.
S-CRP
(mg/l)
B-WBC
(cells/mm
3)
B-lympho
(cells/mm
3)
CSF-leuko
(cells/3 mm
3)
CSF-protein
(g/l)
CSF-glucose
(mmol/l)
1 102 2,700 1,026 5 0.2 3.1
2 204 17,600 1,232 8,704 2.7 2.5
3 346 25,300 759 5,153 3.4 3.4
4 92 4,700 376 230 2.4 2
5 246 17,100 171 1,585 5.7 3.5
6 225 21,500 215 10,000 2.6 4.4
7 226 10,900 218 11,666 7.7 0.5
8 233 25,200 252 3,331 1.8 0.5
9 271 20,700 414 7,253 2.7 1.9
10 159 16,900 507 3,413 2.6 3.3
11 165 16,700 835 3,840 2.8 1.6
12 265 21,500 N.d. 10,000 4.9 0.6
Table 2 Inflammatory markers
in (B) the blood and in the
serum (S) and cerebrospinal
fluid (CSF) obtained at the
time of diagnostic lumbar
puncture from the patients with
invasive meningococcal
disease
WBC = white blood cells;
Lympho = lymphocytes;
Leuko = leukocytes; N.d. = not
determined
Eur J Clin Microbiol Infect Dis (2009) 28:793–799 795(11/12) and in 100% of CSF samples (10/10). MCP-1 and
MIP-1β were detected in 100% of serum samples (12/12) and
in 100% of CSF specimens (10/10). Similarly, leptin was
detectable in 100% of serum specimens (12/12) and 100% of
CSF samples (10/10). In addition, endotoxin was detected in
25% of serum specimens (3/12) and in 90% of CSF samples
(9/10), and cortisol levels were detectable in all serum and
CSF specimens. The serum and CSF concentrations and their
statistical differences are shown in Table 3.
Correlation of serum and CSF inflammatory mediators
with IMD severity
The APACHE II score on day 1 correlated with increased
serum concentrations of IL-6 (r=0.774, P=0.004) and IL-
1ra (r=0.648, P=0.031). The SOFA score on day 1
correlated only with IL-6 serum levels (r=0.773, P=
0.004). In addition, the serum concentration of endotoxin
correlated with GCS (r=0.662, P=0.023). Unlike the
concentrations of inflammatory molecules in the serum,
the CSF concentrations were not associated with IMD
severity.
Correlation between inflammatory mediators in the serum
at admission
IL-1β serum levels correlated significantly with IL-1ra (r=
0.694, P=0.017), IL-6 (r=0.758, P=0.006), IL-8 (r=0.773,
P=0.004), IL-10 (r=0.656, P=0.026), and MIP-1β (r=
0.877, P<0.001). IL-1ra demonstrated a significant corre-
lation with IL-6 (r=0.691, P=0.012), IL-10 (r=0.606, P=
0.043), and MCP-1 (r=0.809, P<0.001). IL-6 serum
concentrations correlated significantly with IL-8 (r=0.773,
P=0.004), IL-10 (r=0.656, P=0.023), and MCP-1 (r=
0.827, P<0.001). MCP-1 levels correlated with IL-8 and
IL-10 serum concentrations (r=0.709, P=0.013; r=0.715,
P=0.011, respectively). In addition, the serum concentra-
tions of endotoxin correlated with the cortisol levels (r=
0.695, P=0.017).
Correlation between inflammatory mediators in the CSF
at admission
IL-1β showed a significant correlation with the CSF levels
of IL-10 (r=0.636, P=0.043). IL-1ra demonstrated a
significant correlation with IL-6 (r=0.867, P<0.001), IL-
10 (r=0.721, P=0.012), and MCP-1 (r=−0.636, P=0.043).
CSF IL-6 levels correlated with IL-10 (r=0.758, P=0.009).
Intrathecal levels of IL-8 demonstrated a significant
correlation with MCP-1 (r=0.879, P<0.001). Endotoxin
concentrations in the CSF correlated with IL-8 (r=0.778,
P=0.005), IL-17 (r=−0.623, P=0.048), MCP-1 (r=0.669,
P=0.029), and MIP-1β (r=0.681, P=0.025). In addition,
CSF cortisol levels correlated with IL-1ra (r=0.636,
P=0.043), IL-6 (r=0.721, P=0.016), and IL-10 (r=0.697,
P=0.022).
Kinetics of serum and CSF inflammatory mediators
and the correlation with IMD severity
Significant decreases in serum concentrations 3–5 days
after the start of the antibiotic treatment were detected for
the following mediators: IL-1ra (P=0.001), IL-6 (P=
0.016), IL-10 (P=0.023), and MIP-1β (P=0.022). In
addition, two routine biomarkers demonstrated significant
changes during this interval: serum CRP levels decreased
(P<0.001), whereas the number of circulating lymphocytes
increased (P=0.002).
With regard to the kinetics of cytokines in CSF during
the course of IMD, significant decreases were demonstrated
in the concentrations of IL-1β (P=0.02), IL-1ra (P<0.001),
IL-6 (P<0.001), IL-8 (P=0.008), MCP-1 (P=0.001), and
MIP-1β (P=0.003). The kinetics of serum as well as the
CSF levels of IL-1ra, IL-6, MCP-1, and MIP-1β are shown
in Fig. 1. Similar to cytokines and chemokines, the
endotoxin levels decreased over time (P=0.016). As
expected, the number of leukocytes in the CSF as well as
the CSF protein concentrations declined (P=0.003 for both
markers), and the CSF glucose level increased (P=0.049).
Unlike serum parameters, the kinetics of some CSF
biomarkers demonstrated a significant correlation with the
IMD severity: Δ cortisol correlated with APACHE II score
(r=0.690, P=0.04) and Δ glucose and Δ IL-6 correlated
with SOFA score (r=−0.860, P=0.003; r=0.733, P=0.039,
respectively).
Table 3 Difference between serum and CSF concentrations of
inflammatory molecules in specimens obtained at admission to the
hospital
Parameter Serum CSF P-value
a
IL-1b (pg/ml) 38 (112) 974 (1,118) 0.031
IL-1ra (pg/ml) 27,978 (14,234) 58,710 (33,025) 0.029
IL-6 (pg/ml) 7,549 (12,895) 59,575 (28,462) <0.001
IL-8 (pg/ml) 2,263 (5,325) 33,760 (19,118) <0.001
IL-10 (pg/ml) 2,432 (4,762) 986 (1,457) N.s.
IL-17 (pg/ml) 6 (6) 45 (109) N.s.
MCP-1 (pg/ml) 2,139 (2,592) 23,025 (14,134) <0.001
MIP-1b (pg/ml) 653 (1,657) 49,207 (42,336) 0.006
Leptin (pg/ml) 6,496 (8,846) 53 (42) 0.002
Endotoxin (EU) 13 (43) 133 (140) N.s.
Cortisol (nmol/ml) 247 (358) 157 (108) N.s.
N.s. = not significant; EU = endotoxin unit
aPaired t-test and Wilcoxon signed rank test, as appropriate
Data are presented as means (standard deviation)
796 Eur J Clin Microbiol Infect Dis (2009) 28:793–799Discussion
The inflammatory response elicited by N. meningitidis is
considered to be the major factor responsible for the
outcome of IMD. Therefore, we analyzed the concentra-
tions and kinetics of different molecules that are known to
be related to inflammation in the CSF and serum during the
course of IMD.
Our results demonstrated significant compartmentaliza-
tion of the immune response in the subarachnoid space,
which has been already reported in meningococcal menin-
gitis, as well as in community-acquired bacterial meningitis
of other etiology [14, 15]. Moreover, cytokines and
chemokines that were concentrated in the CSF were also
detectable in the serum in the majority of IMD patients. It is
well known that IL-6 and IL-8 can be used in the laboratory
Fig. 1 The kinetics of serum
and cerebrospinal fluid (CSF)
cytokine levels during invasive
meningococcal disease
Eur J Clin Microbiol Infect Dis (2009) 28:793–799 797diagnostics of bacterial meningitis and sepsis [16, 17].
However, our findings also indicate the potential use of IL-
1ra, MCP-1, and MIP-1β for the laboratory diagnostics of
sepsis, as well as bacterial meningitis. Similar to previous
studies, we detected LOS in 90% of CSF specimens,
whereas only 33% of serum samples were positive for N.
meningitidis endotoxin [18]. This finding suggests that the
inflammatory response in the brain is triggered by LOS,
whichisalsosupportedbythesignificantcorrelationobserved
between high endotoxin levels in the CSF and increased
intrathecal concentrations of IL-8, IL-17, MCP-1, and MIP-
1β. It is likely that LOS released from N. meningitidis in the
subarachnoid space activates brain-resident immune cells
(e.g., microglia, meningeal macrophages, and macrophages
in Virchow-Robin spaces). These cells produce chemokines
after stimulation, the role of which is apparent: MCP-1 and
MIP-1β attract monocytes to the subarachnoid space,
whereas IL-8 is responsible for the migration of neutrophils
[19, 20]. In addition, high serum concentrations of MCP-1
and MIP-1β were detected in FMS, whereas meningococcal
meningitis was associated with significantly lower concen-
trations of these chemokines [21].
The situation in the blood compartment is more
complicated because LOS levels were detectable in only
1/4 of the specimens, in spite of a significantly stimulated
immune response. Thus, we can speculate about the
stimulus that led to the systemic inflammation. It seems
probable that the systemic response was elicited in our
patients by LOS. The low or undetectable LOS levels
measured in the blood of our patients with meningococcal
meningitis can be explained by a low-grade bacterial load
already found in patients with milder forms of IMD [22].
Another possible mechanism might be a rapid clearance of
this molecule from the systemic circulation occurring via
neutralization by host protein—bactericidal/permeability-
increasing protein [23]. Finally, it might be possible that the
triggers were proinflammatory cytokines released from the
site of infection (i.e., the brain). However, this is unlikely,
because focal infections such as meningitis or pneumonia
are characterized by a highly compartmentalized immune
response [15, 24].
It is generally believed that proinflammatory responses
prevail at the site of the infection, whereas the systemic
response is anti-inflammatory [25]. This idea partially
conflicts with our findings of the highly elevated levels of
anti-inflammatory mediators (i.e., IL-1ra, IL-10, and corti-
sol) in the CSF detected in the majority of our patients. In
fact, we observed the simultaneous activation of intrathecal
pro- and anti-inflammatory immune responses, which may
reflect specific mechanisms of host responses in the brain.
The role of chemokines in the subarachnoid space during
bacterial meningitis has already been discussed. In addition,
IL-6, which is produced in the brain by resident cells (i.e.,
astroglia and microglia) and migrating immune cells (i.e.,
neutrophils and macrophages), also has proinflammatory
activities [26]. It is worth noting that this cytokine can
stimulate the activity of glial cells, playing very important
roles in the brain’s defense against bacterial infection [27].
Despite the fact that meningitis was the prevailing
clinical form of IMD in this study, the serum levels of IL-
6 only correlated positively with IMD severity evaluated at
the time of admission to the hospital. Waage et al. [28]
previously reported similar findings in patients with a fatal
course of IMD. In agreement with their results, we
observed extremely high IL-6 serum levels in a patient
(patient 1; Table 1) who died as a result of FMS [29]. When
we assessed for an association between the kinetics of IL-6
and IMD severity, no correlation was found. Conversely,
we observed different results in the CSF, with a significant
correlation of IMD severity and kinetics of IL-6 and
cortisol, and no correlation with their baseline levels. This
is partially in discrepancy with the results of one study in
which high baseline CSF cortisol levels were detected in
patients with a severe course of adult community-acquired
bacterial meningitis [15]. This difference is probably due to
an alteration in cortisol metabolism during IMD. The
observed correlation between the rapid decline of CSF IL-
6 levels and IMD severity is a novel finding, which
contradicts previous reports of persistent IL-6 activity in
the CSF of children with bacterial meningitis [30].
In conclusion, our data illustrate the complex relation-
ship between proinflammatory and anti-inflammatory
responses during the course of IMD. The differences
observed between the investigated biomarkers with regard
to their kinetics, correlation with IMD severity, compart-
mentalization of production, as well as their complex
relationships, warrant a careful approach in the study of
IMD pathophysiology. Multiplex assays seem to be a good
option for studies of these complexities.
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